Holen Sie sich die Stockscreener-App
20.22
2.28%
0.45
Handel nachbörslich:
20.22
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
How Enliven Therapeutics Inc. stock performs during market volatilityGap Up & Entry Point Strategy Guides - Newser
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Comprehensive Market Scan Reports - thegnnews.com
Analyzing Enliven Therapeutics Inc. with risk reward ratio chartsQuarterly Profit Review & Stock Portfolio Risk Control - Newser
We're Not Very Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn Rate - Yahoo Finance
Real time social sentiment graph for Enliven Therapeutics Inc.Trade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Enliven Therapeutics: Cash runway could fund ops into 2029 - BizWest
Enliven Therapeutics shares fall 1.58% intraday after reporting positive Phase 1 clinical trial data for ELVN-001 in CML. - AInvest
BTIG reiterates Buy rating on Enliven Therapeutics stock with $45 target By Investing.com - Investing.com South Africa
Technical signs of recovery in Enliven Therapeutics Inc.Forecast Cut & Consistent Profit Trading Strategies - Newser
Chart overlay techniques for tracking Enliven Therapeutics Inc.Weekly Trend Recap & Low Risk Entry Point Guides - Newser
Combining price and volume data for Enliven Therapeutics Inc.Weekly Trade Report & Community Shared Stock Ideas - Newser
Sectors Driving Future Growth for Enliven Therapeutics Inc. StockBuy Signal & Weekly Breakout Watchlists - Newser
Multi factor analysis applied to Enliven Therapeutics Inc.Portfolio Risk Report & Free Fast Gain Swing Trade Alerts - Newser
Enliven Therapeutics Reports Positive Trial Results and Strong Financials - TipRanks
Enliven Posts Loss Beat and Cash Surge - The Motley Fool
Enliven Posts Loss Beat and Cash Surge - Nasdaq
Enliven Therapeutics, Inc Q2 Loss Climbs - Nasdaq
Enliven Therapeutics: A High-Conviction Biotech Play in Precision Oncology - AInvest
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - PR Newswire
Published on: 2025-08-13 08:33:59 - Newser
What MACD signals say about Enliven Therapeutics Inc.M&A Rumor & Low Volatility Stock Suggestions - Newser
Is Enliven Therapeutics Inc. stock bottoming outJuly 2025 Movers & Comprehensive Market Scan Insights - Newser
Will Enliven Therapeutics Inc. stock split in the near futureTrading Watchlist with Real Time Filters - Newser
Unlocking Value Post-Lock-Up: Analyzing Enliven Therapeutics' Recent Equity Raise and Implications for Investor Strategy - AInvest
The Strategic Timing of Enliven Therapeutics' $230M Raise and Lock-Up Expiration: A Playbook for Warrant Holders and Institutional Investors - AInvest
What makes Enliven Therapeutics Inc. stock price move sharplyFree Breakout Confirmation With Entry Tracker - Newser
Can volume confirm reversal in Enliven Therapeutics Inc.Free Fast Return Equity Trade Forecast - Newser
Using AI based signals to follow Enliven Therapeutics Inc.Equity Forecast with Predictive AI Screener - Newser
Enliven Therapeutics' COO Patel Anish sells shares on August 7 at $18.2 and $18.93. - AInvest
Institutional scanner results for Enliven Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
RSI Suggests Rebound May Be Near in Enliven Therapeutics Inc.Growth Based Investment Plan Guidance Highlighted - metal.it
Enliven Therapeutics (ELVN) Projected to Post Earnings on Tuesday - Defense World
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.20 - Defense World
Federated Hermes Inc. Has $1.36 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Chartists Watching For Breakout in Enliven Therapeutics Inc.Stable Entry High Return Opportunities in Focus - metal.it
Enliven Therapeutics Inc. Inches Above Key Support — Safe to HoldReliable Investment Entry Signals Confirmed by Charts - metal.it
Why is Enliven Therapeutics Inc. stock attracting strong analyst attentionBuild a portfolio that outperforms the market - Jammu Links News
What are the latest earnings results for Enliven Therapeutics Inc.Track emerging stocks with high growth potential - Jammu Links News
Should I hold or sell Enliven Therapeutics Inc. stock in 2025Achieve rapid returns with smart investment plans - Jammu Links News
What analysts say about Enliven Therapeutics Inc. stockAchieve breakthrough financial results - Jammu Links News
Is it the right time to buy Enliven Therapeutics Inc. stockDiscover high-impact investment opportunities - Jammu Links News
Is Enliven Therapeutics Inc. a good long term investmentAchieve consistent profits with proven methods - Jammu Links News
How does Enliven Therapeutics Inc. generate profit in a changing economyDynamic profit opportunities - Jammu Links News
Is Enliven Therapeutics Inc. a growth stock or a value stockGet alerts on high-potential market moves - Jammu Links News
How does Enliven Therapeutics Inc. compare to its industry peersDiscover breakthrough stocks with expert help - Jammu Links News
Does Enliven Therapeutics Inc. stock perform well during market downturnsFree AI-Backed Trading Signals - Jammu Links News
Is Enliven Therapeutics Inc. stock overvalued or undervaluedBreakout Stocks Tracker For Consistent Profits - jammulinksnews.com
How strong is Enliven Therapeutics Inc. company’s balance sheetFree Stock Recommendation With Proven Results - jammulinksnews.com
Using economic indicators to assess Enliven Therapeutics Inc. potentialValue Holding Return Summary With Outlook - Newser
What MACD and RSI say about Enliven Therapeutics Inc.Free Quick Gain Stock Watch With Indicators - Newser
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):